K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy.
K-means clustering-based analysis of quantitative ultrafast DCE-MRI for predicting breast cancer response to neoadjuvant chemotherapy. J Appl Clin Med Phys. 2026 Jan; 27(1):e70439.
PMID: 41456332
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial.
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 Dec 01; 8(12):e2549109.
PMID: 41632146
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer.
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancer. Res Sq. 2025 Jul 07.
PMID: 40671797
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer.
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
PMID: 40285528
Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer.
Treatment, toxicity, and mortality after subsequent breast cancer in female survivors of childhood cancer. Nat Commun. 2025 Mar 31; 16(1):3088.
PMID: 40164623
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials.
Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated HR+ and HER2- mBC: a meta-analysis of TROPiCS-02 and EVER-132-002 trials. Ther Adv Med Oncol. 2025; 17:17588359251320285.
PMID: 40093981
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
PMID: 39928262
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 02 03; 8(2):e2460243.
PMID: 39960669
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.
PMID: 39561272
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2024 Dec 09; 10781552241305417.
PMID: 39648753